PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...
Healio

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...